AtriCure wraps up its $34M deal for an ablation specialist

AtriCure ($ATRC) has closed its deal for California's Estech, handing over $34 million to get its hands on some new surgical ablation technologies. AtriCure, a major player in the atrial fibrillation device market, expects Estech's instruments to help pad its earnings starting in 2015. More

Suggested Articles

A decade-long study found that patients with early breast cancer may be spared radiation procedures that span the whole breast.

A cell therapy for Parkinson’s disease starts out simple, but quickly gets complicated with the potential for immune responses and cancer mutations.

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.